Teva Expects $1B After Closing, $500M of Cost Savings from Purchase (CEPH. TEVA)

Teva TEVA says, "Cephalon CEPH enterprise value includes conversion of convertibles... Cephalon is `great strategic fit'... sees $500M of cost savings from Cephalon purchase... sees cost savings in third year after closing... expects to have $1 billion in cash after closing... will have debt-ebitda ratio of 2 after closing... will have financial flexibility afer Cephalon purchase... purchase values Cephalon generic risk appropriately."